Cure My Disease

Don't miss your cure!

 Log in / Sign up

French study tracks Ivosidenib's Real-World impact on Hard-to-Treat leukemia

NCT ID NCT06377579

Recruiting now Disease control Sponsor: French Innovative Leukemia Organisation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes 250 adults with a specific genetic subtype of acute myeloid leukemia (AML) who received the targeted drug Ivosidenib through a compassionate use program in France. Researchers will track survival and treatment response in patients receiving the drug as a first treatment or after relapse. The goal is to gather real-world evidence on how well Ivosidenib works outside of clinical trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML, ADULT

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amiens CHU

    NOT_YET_RECRUITING

    Amiens, France

    Contact Email: •••••@•••••

  • Angers CHU

    NOT_YET_RECRUITING

    Angers, France

    Contact Email: •••••@•••••

  • Bayonne CH

    NOT_YET_RECRUITING

    Bayonne, France

    Contact Email: •••••@•••••

  • Besançon CHU

    NOT_YET_RECRUITING

    Besançon, France

    Contact Email: •••••@•••••

  • Bordeaux CHU

    NOT_YET_RECRUITING

    Pessac, France

    Contact Email: •••••@•••••

  • CHU Estaing

    RECRUITING

    Clermont-Ferrand, France

    Contact Email: •••••@•••••

  • Créteil CHU HENRI MONDOR

    RECRUITING

    Créteil, France

    Contact Email: •••••@•••••

  • DUNKERQUE-Hôpital Alexandra Lepève

    RECRUITING

    Dunkirk, 59385, France

    Contact Email: •••••@•••••

    Contact

  • Grenoble CHU

    NOT_YET_RECRUITING

    Grenoble, France

    Contact Email: •••••@•••••

  • ICANS - Institut de cancérologie de strasbourg europe

    NOT_YET_RECRUITING

    Strasbourg, France

    Contact Email: •••••@•••••

  • Le Mans CH

    NOT_YET_RECRUITING

    Le Mans, France

    Contact Email: •••••@•••••

  • Lyon sud CHU

    NOT_YET_RECRUITING

    Lyon, France

    Contact Email: •••••@•••••

  • Marseille IPC

    NOT_YET_RECRUITING

    Marseille, France

    Contact Email: •••••@•••••

  • Meaux CH de l'Est francilien

    RECRUITING

    Meaux, France

    Contact Email: •••••@•••••

  • Montpellier - Chu Saint Eloi

    NOT_YET_RECRUITING

    Montpellier, France

    Contact Email: •••••@•••••

  • Mulhouse Chu

    RECRUITING

    Mulhouse, 68100, France

    Contact

    Contact Email: •••••@•••••

  • Nantes CHU

    RECRUITING

    Nantes, France

    Contact Email: •••••@•••••

  • Nice CHU

    NOT_YET_RECRUITING

    Nice, France

    Contact Email: •••••@•••••

  • Orléans CHU

    NOT_YET_RECRUITING

    Orléans, 45000, France

    Contact Email: •••••@•••••

    Contact

  • Paris Saint Louis

    NOT_YET_RECRUITING

    Paris, France

    Contact Email: •••••@•••••

  • Toulouse - IUCT Oncopole - Service d'Hématologie

    NOT_YET_RECRUITING

    Toulouse, France

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.